Oncology Corporate Profile
Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar's compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to 'find, treat and follow' malignancies in a highly selective way.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|I-124-CLR1404||positron emission tomography (PET)||Glioblastoma Multiforme (GBM)||II|
|CLR 131||radiopharmaceutical||Multiple Myeloma||I|
|CLR 131||radiopharmaceutical||Various cancer types||I|
View additional information on product candidates here »